
Glaucoma is an eye disease that can lead to a permanent loss of vision. Glaucoma generally provides no warning signs or symptoms of disease, making testing an important part of a full vision exam.

Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which causes loss of vision. Abnormally high pressure inside your eye (intraocular pressure) usually, but not always, causes this damage.
Glaucoma is the second leading cause of blindness. Sometimes called the silent thief of sight, glaucoma can damage your vision so gradually you may not notice any loss of vision until the disease is at an advanced stage. The most common type of glaucoma, primary open-angle glaucoma, often has no noticeable signs or symptoms.
Early diagnosis and treatment can minimize or prevent optic nerve damage and limit glaucoma-related vision loss. It's important to get your eyes examined regularly, and make sure your eye doctor measures your intraocular pressure.
iStent inject® is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate primary open-angle glaucoma. Key advantages to using the device during cataract surgery include:
With iStent infinite®, a trabecular micro-bypass device from Glaukos, Dr. Ehrenhaus can reduce intraocular pressure (IOP) in cases of open-angle glaucoma where previous medical and surgical interventions have failed. As one of the smallest implantable devices in the human body, iStent infinite® restores the eye’s natural ability to drain fluid and reduce IOP.
This innovative technology represents the latest advancements in care and offers the first micro-invasive, standalone implantable option to address patient non-compliance issues and disease progression.
When strategically placed via a precision-engineered injector system, iStent infinite® stents improve IOP control and reduce a patient’s dependence on glaucoma medication.
iStent inject® creates two patent bypass pathways through the trabecular meshwork—the main source of resistance for aqueous outflow—resulting in multi-directional flow through Schlemm’s canal. It is also one of the smallest medical devices known to be implanted in the human body. These advantages are designed to provide exceptional results in a truly micro-invasive approach.
With iStent inject®, two multi-directional stents are placed two to three clock hours apart. Together, they are designed to deliver access to multiple collector channels and arcs of flow spanning five to six clock hours. iStent inject® may also help re-establish flow in previously dormant outflow channels.
Designed to maximize benefits while minimizing long-term complications, iStent inject® supports optimal outcomes after cataract surgery. In both U.S. pivotal studies and worldwide use, it has demonstrated an excellent safety profile comparable to cataract surgery alone. Additional benefits include:
The iStent inject® System is engineered to provide an enhanced surgical experience and ensure confident delivery in every procedure. From its proprietary stent design to the streamlined injector system, iStent inject® is designed to be straightforward in use, precise in placement, and predictable in performance.
Glaucoma is a group of progressive eye conditions that damage the optic nerve and can lead to permanent vision loss. Elevated intraocular pressure (IOP) is a common risk factor but glaucoma can occur even when IOP is within the normal range. Damage from glaucoma typically affects peripheral vision first and may progress slowly without obvious symptoms.
Because vision loss from glaucoma is permanent, early detection and treatment focus on preserving remaining vision and preventing further nerve damage. Regular comprehensive eye exams that include optic nerve assessment and pressure measurement are essential for people at risk. Timely follow-up and treatment adjustments help limit long-term vision loss.
The most common forms of glaucoma include primary open-angle glaucoma and angle-closure glaucoma, while normal-tension glaucoma and secondary glaucomas occur under specific circumstances. Primary open-angle glaucoma develops gradually as drainage through the trabecular meshwork becomes less efficient, often with few or no early symptoms. Angle-closure glaucoma occurs when the drainage angle becomes blocked, which can produce a rapid rise in pressure and requires urgent evaluation.
Secondary glaucomas arise from identifiable causes such as inflammation, trauma, steroid use, or other eye diseases and may require targeted management of the underlying condition. Distinguishing the type of glaucoma is important because it guides monitoring intervals and treatment choices. Your eye specialist will use examination and diagnostic testing to classify the condition accurately.
Many people with early glaucoma have no symptoms, which is why it is often called the silent thief of sight. Gradual loss of peripheral vision, difficulty with night vision, or a narrowing of the visual field are common signs that may appear as the disease advances. Sudden eye pain, nausea, vomiting, severe headache, and blurred vision with halos around lights can indicate an acute angle-closure event and require immediate medical attention.
If you have risk factors such as a family history of glaucoma, older age, high myopia, a history of eye trauma, or chronic steroid use, schedule regular eye exams even in the absence of symptoms. Prompt evaluation and testing can detect changes before irreversible vision loss occurs. Report any sudden changes in vision or eye discomfort to your eye care provider right away.
Diagnosis of glaucoma is based on a combination of clinical findings and diagnostic tests rather than a single measurement. Common assessments include tonometry to measure intraocular pressure, gonioscopy to inspect the drainage angle, dilated examination of the optic nerve, visual field testing to evaluate functional loss, and optical coherence tomography (OCT) to measure retinal nerve fiber layer thickness. Repeated measurements over time are often necessary to establish a baseline and detect progression.
Because glaucoma can present differently between patients, clinicians correlate structural signs in the optic nerve and retinal nerve fiber layer with functional changes on visual field testing to arrive at a diagnosis. Additional testing may be performed to identify secondary causes or to monitor response to therapy. Accurate documentation and serial testing allow clinicians to tailor treatment and follow-up frequency to each patient’s risk profile.
Treatment for glaucoma aims to lower intraocular pressure to slow or stop optic nerve damage and preserve vision. First-line therapy often includes topical medications (eye drops) that reduce aqueous production or improve outflow, while laser procedures such as selective laser trabeculoplasty (SLT) can be used as primary or adjunctive therapy. For patients who do not achieve target pressure with drops or laser, surgical options range from minimally invasive glaucoma surgeries (MIGS) to more traditional filtering procedures and drainage devices.
Choice of therapy depends on the type and severity of glaucoma, the patient’s anatomy and general health, medication tolerance and adherence, and long-term treatment goals. Combination approaches are common and may include cataract surgery with a MIGS device, standalone ab-interno implants, or more extensive filtration surgeries for advanced disease. Your eye specialist will discuss risks, benefits, and expected outcomes to determine the most appropriate plan.
Minimally invasive glaucoma surgeries (MIGS) are a category of procedures designed to lower IOP with less tissue disruption than traditional glaucoma surgeries. Devices like iStent inject are typically implanted during cataract surgery for patients with mild-to-moderate primary open-angle glaucoma to enhance natural outflow through the trabecular meshwork. iStent infinite is a micro-bypass option that can be used as a standalone implant in more advanced or refractory cases to restore multiple outflow pathways.
Advantages of MIGS devices include smaller incisions, shorter recovery times, and preservation of conjunctival tissue, which may maintain options for future treatments. Not every patient is a candidate for MIGS, and the choice of device depends on individual anatomy, disease severity, and prior treatments. Discussing candidacy, expected outcomes, and postoperative care with a surgeon experienced in anterior segment procedures helps determine whether MIGS is appropriate.
Selective laser trabeculoplasty (SLT) uses low-energy laser pulses to target pigmented cells in the trabecular meshwork and stimulate a biological response that can improve aqueous outflow and lower IOP. It is an outpatient procedure that is often considered for patients with primary open-angle glaucoma and can be used as an alternative to or in combination with topical medications. SLT is repeatable and may reduce the number of glaucoma drops a patient requires, although individual responses vary.
Recovery from SLT is typically quick, with most patients experiencing minimal discomfort and returning to normal activities shortly after the procedure. Short-term inflammation is common and is managed with prescribed topical medications, and a follow-up visit shortly after treatment checks for pressure spikes. Regular monitoring is necessary to assess durability of the response and determine if additional therapy is needed.
Follow-up frequency for glaucoma depends on the diagnosis, disease severity, stability, and the treatments being used. Newly diagnosed patients or those with changing treatment plans may be seen every three months or more frequently until the condition stabilizes, while stable patients with well-controlled disease may be monitored every six to twelve months. High-risk patients, such as those with progressive optic nerve changes or rapidly worsening visual fields, require closer follow-up and more frequent testing.
At follow-up visits clinicians typically measure IOP, perform optic nerve assessment, and obtain functional and structural tests such as visual fields and OCT as indicated. Consistent testing at each visit provides trend information that is critical for detecting progression early. Adhering to the recommended schedule and reporting new symptoms promptly are important parts of preserving vision.
Recovery expectations vary by procedure, but many minimally invasive procedures have relatively quick recoveries with modest discomfort and gradual visual improvement. After surgery or laser treatment you will typically use prescribed topical medications, attend scheduled follow-up visits to monitor pressure and healing, and avoid strenuous activity or heavy lifting for a defined period. Your surgeon will provide specific postoperative instructions including signs to watch for, such as increasing pain, sudden vision loss, or redness, which require urgent evaluation.
Some procedures carry risks such as transient IOP spikes, inflammation, bleeding, infection, or the potential need for additional interventions if target pressure is not achieved. Long-term follow-up remains important because glaucoma is chronic and may progress despite treatment. Clear communication with your eye care team and adherence to follow-up appointments support the best possible outcomes.
Cornea and anterior segment specialists have focused training in the front structures of the eye and advanced experience with procedures that address both corneal and angle anatomy. This expertise is valuable when evaluating complex anterior segment anatomy, planning combined cataract and glaucoma procedures, or performing minimally invasive glaucoma surgeries such as trabecular micro-bypass implants. Dr. Michael Ehrenhaus is experienced in a range of anterior segment and corneal procedures and can assess whether specialized surgical or medical approaches are appropriate for each patient.
Coordinated care with optometrists and other eye-care professionals supports comprehensive management of glaucoma patients, particularly when multiple ocular conditions coexist. New York Cornea Consultants & Aesthetics offers access to modern diagnostics and a multidisciplinary approach to tailor monitoring and treatment plans. If you have concerns about glaucoma or are due for an evaluation, schedule a comprehensive exam to establish a baseline and discuss individualized options.
